Navigation Links
Noridian Medicare Now Covers Renessa(R) Treatment for Incontinence in Women
Date:2/24/2009

NEWARK, Calif., Feb. 24 /PRNewswire/ -- Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that Noridian Administrative Services, LLC, a regional Medicare carrier administering benefits in nine states, is now covering the non-surgical Renessa treatment for women with stress urinary incontinence (SUI). Noridian currently administers benefits for approximately 4 million Medicare beneficiaries in Alaska, Arizona, Montana, North and South Dakota, Oregon, Utah, Washington and Wyoming.

According to Noridian's website, the insurer "will now cover CPT 0193T, transurethral, radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence. This includes the Renessa transurethral collagen radiofrequency denaturation procedure." The website goes on to state that "coverage will be allowed when the procedure is performed consistent with FDA labeling and in accordance with the indications supported by peer-reviewed literature." The policy specifies that coverage only applies to cases of moderate to severe female SUI.

"We are very pleased with Noridian's decision," said Debra Reisenthel, Novasys Medical President and Chief Executive Officer. "Noridian is the first regional Medicare carrier to offer coverage for the Renessa procedure, and joins other private insurers, including Aetna US Healthcare, in providing coverage for this safe and effective non-surgical treatment for women who suffer from the debilitating effects of SUI," she continued.

Female Stress Urinary Incontinence

SUI is the involuntary leakage of urine associated with laughing, coughing, sneezing and recreational activities. The condition is caused by a variety of factors, most commonly childbirth, and often restricts the social, professional, and personal lives of a significant number of women. With currently available surgical and non-surgical SUI therapies, many patients and physicians have concerns about safety, recovery, compliance, and/or effectiveness.

The FDA-cleared Renessa System includes a small probe which a physician passes through the natural opening of the urethra (transurethral). The probe heats multiple small treatment sites in the submucosa of the bladder neck and upper urethra, denaturing the patient's own collagen in the tissue, thereby reducing or eliminating leaks. The Renessa treatment can be performed in the convenience of a physician's office using local anesthesia. There are no incisions, bandages or dressings required. Recovery is rapid and comfortable, with minimal post-procedure limitations. The Renessa treatment offers an option for women who have tried conservative therapies such as Kegel exercises or biofeedback without success, but who cannot have or do not desire an invasive surgical procedure. To date, over 300 urologists, urogynecologists and gynecologists in 40 states have been trained and have performed the Renessa procedure in over 2500 patients.

About Novasys Medical

Novasys Medical, Inc. is a privately held, venture-backed company which develops innovative therapies in women's health. The company's initial focus is the development and commercialization of the Renessa System, a proprietary, non-surgical approach to the treatment of female stress urinary incontinence (SUI).

For more information, please visit http://www.novasysmedical.com or call (510) 226-4060.


'/>"/>
SOURCE Novasys Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. QMed, Inc. Reports July Medicare SNP Enrollments
2. Change in Medicare and Medicaid Legislation Creates Market for Antimicrobial Coatings In the U.S.
3. House and Senate Pass Medicare Legislation to Freeze 2008 Reimbursement for Therapeutic Radiopharmaceuticals at 2007 Levels
4. Medicare Coverage Recommended for In-Home Sleep Testing
5. MedicareCRM(TM) to Speak at IIR Medicare Advantage Congress
6. STAAR Surgicals Collamer(R) IOL Designated as a New Technology Intraocular Lens by the Centers for Medicare and Medicaid Services
7. Medicare Approves in Home Sleep Apnea Testing
8. Medtronic Unit to Pay $75 Million to Settle Whistleblower Medicare Fraud Case
9. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
10. Arcadian Health Plan Addresses Medicare Doctor Payment Cuts
11. Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing and the Importance of New Medicare-Related E-Prescribing Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... FireflySci has been ... found among its diverse customer base. The latest entry in this field is ... including BTX and Bio-Rad. FireflySci is introducing three distinct varieties including a 10x1mm, ...
(Date:1/12/2017)... North Carolina (PRWEB) , ... January 12, 2017 , ... ... called the Eureka Index – a process that evaluates the patent estate of a ... Immunolight LLC , a biomedical firm leading the way in technologies that transform ...
(Date:1/12/2017)... ... 2017 , ... After her brain cancer became resistant to ... a few months to live. Now a paper publishing January 17 in the ... increased both the quantity and quality of her life: Adding the anti-malaria drug ...
(Date:1/12/2017)... Pune, India , January 12, 2017 A new report ... and End Users - Global Opportunity Analysis and Industry Forecast, 2014-2022," projects that the ... million in 2015, growing at a CAGR of 15.07% during the forecast period. ... ... Research Logo ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016 Advancements ... experience, health wellness and wellbeing (HWW), and ... in three new passenger vehicles begin to ... gesture recognition, heart beat monitoring, brain wave ... facial monitoring, and pulse detection. These will ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE ... priced an offering of €500.0 million principal amount of its ... amount of its 2.425% senior unsecured notes due 2026. ... occur on December 13, 2016, subject to the satisfaction of customary ... basis. The Company intends to ...
Breaking Biology News(10 mins):